Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma

J Transl Med. 2012 Aug 31;10:181. doi: 10.1186/1479-5876-10-181.

Abstract

Background: Melanoma antigen D1 (MAGED1) is a member of the type II melanoma antigen (MAGE) family. The down-regulation of MAGED1 expression has been shown in breast carcinoma cell lines and in glioma stem cells and may play an important role in apoptosis and anti-tumorigenesis. However, there is no report on its clinical role in colorectal cancer (CRC).

Methods: We examined the expression of MAGED1 by qPCR in colorectal cancer tissues and their adjacent non-tumorous tissues taken from 6 cases and performed Western blotting and IHC analyses. In addition, we analyzed MAGED1 expression in 285 clinicopathologically characterized colorectal cancer patients.

Results: MAGED1 expression was significantly down-regulated in colorectal cancer tissues compared with adjacent non-tumorous tissues and was associated with clinical stage (p < 0.001), T classification (p = 0.001), N classification (p < 0.001), M classification (p < 0.001) and pathologic differentiation (p = 0.002). Patients with lower MAGED1 expression had a shorter survival time than those with higher MAGED1 expression. Univariate and multivariate analyses indicated that MAGED1 expression was an independent prognostic factors (p < 0.001).

Conclusions: MAGED1 may serve as a novel prognostic biomarker of human colorectal cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm / immunology*
  • Biomarkers, Tumor / immunology*
  • Blotting, Western
  • Colorectal Neoplasms / immunology*
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Melanoma / immunology*
  • Middle Aged
  • Neoplasm Proteins / immunology*
  • Polymerase Chain Reaction
  • Prognosis
  • Survival Analysis

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • MAGED1 protein, human
  • Neoplasm Proteins